Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders

Human Molecular Genetics

Volumn 22, Issue R1, 2013, Pages

  Janssens, Jonathan ^a,b   Van Broeckhoven, Christine ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TAR DNA BINDING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; FRONTOTEMPORAL DEMENTIA; HUMAN; MISSENSE MUTATION; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN HOMEOSTASIS; TDP 43 PROTEINOPATHY;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BRAIN; DNA-BINDING PROTEINS; FRONTOTEMPORAL LOBAR DEGENERATION; GENETIC VARIATION; HUMANS; MUTATION; PROTEINS; TDP-43 PROTEINOPATHIES;

EID: 84884777626     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt349     Document Type: Article

References (169)

1. Geser, F., Martinez-Lage, M., Kwong, L.K., Lee, V.M. and Trojanowski, J.Q. (2009) Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases. J. Neurol., 256, 1205-1214.
2. Van Langenhove, T., van der Zee, J., and Van Broeckhoven, C. (2012) The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. Ann. Med., 44, 817-828.
3. Neary, D., Snowden, J., and Mann, D. (2005) Frontotemporal dementia. Lancet Neurol., 4, 771-780.
4. Rabinovici, G.D., and Miller, B.L. (2010) Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis, and management. CNS Drugs, 24, 375-398.
5. Cerami, C., Scarpini, E., Cappa, S.F., and Galimberti, D. (2012) Frontotemporal lobar degeneration: current knowledge, and future challenges. J. Neurol., 259, 2278-2286.
6. Charcot, J.M., and Joffroy, A. (1869) Deux cas d'atrophie musculaire progressive: avec lésions de la substance grise et des faisceaux antérolatéraux de la moelle épiniére. V. Masson, Paris.
7. Brooks, B.R., Miller, R.G., Swash, M., and Munsat, T.L. (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral. Scler. Other Motor Neuron Disord., 1, 293-299.
8. Rowland, L.P., and Shneider, N.A. (2001) Amyotrophic lateral sclerosis. N. Engl. J. Med., 344, 1688-1700.
9. Kiernan, M.C., Vucic, S., Cheah, B.C., Turner, M.R., Eisen, A., Hardiman, O., Burrell, J.R., and Zoing, M.C. (2011) Amyotrophic lateral sclerosis. Lancet, 377, 942-955.
10. Lomen-Hoerth, C., Anderson, T., and Miller, B. (2002) The overlap of amyotrophic lateral sclerosis, and frontotemporal dementia. Neurology, 59, 1077-1079.
11. Murphy, J.M., Henry, R.G., Langmore, S., Kramer, J.H., Miller, B.L., and Lomen-Hoerth, C. (2007) Continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch. Neurol., 64, 530-534.
12. Ringholz, G.M., Appel, S.H., Bradshaw, M., Cooke, N.A., Mosnik, D.M., and Schulz, P.E. (2005) Prevalence, and patterns of cognitive impairment in sporadic ALS. Neurology, 65, 586-590.
13. Phukan, J., Pender, N.P., and Hardiman, O. (2007) Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol., 6, 994-1003.
14. Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C., Chou, T.T., Bruce, J., Schuck, T., Grossman, M., Clark, C.M. et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration, and amyotrophic lateral sclerosis. Science, 314, 130-133.
15. Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., and Oda, T. (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration, and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun., 351, 602-611.
16. Lee, E.B., Lee, V.M., and Trojanowski, J.Q. (2012) Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci., 13, 38-50.
17. Chen-Plotkin, A.S., Lee, V.M., and Trojanowski, J.Q. (2010) TAR DNA-binding protein 43 in neurodegenerative disease. Nat. Rev. Neurol., 6, 211-220.
18. Geser, F., Robinson, J.L., Malunda, J.A., Xie, S.X., Clark, C.M., Kwong, L.K., Moberg, P.J., Moore, E.M., Van Deerlin, V.M., Lee, V.M. et al. (2010) Pathological 43-kDa transactivation response DNA-binding protein in older adults with, and without severe mental illness. Arch. Neurol., 67, 1238-1250.
19. Wang, H.Y., Wang, I.F., Bose, J., and Shen, C.K. (2004) Structural diversity, and functional implications of the eukaryotic TDP gene family. Genomics, 83, 130-139.
20. Ayala, Y.M., Pantano, S., D'Ambrogio, A., Buratti, E., Brindisi, A., Marchetti, C., Romano, M., and Baralle, F.E. (2005) Human, Drosophila, and C. elegans TDP43: nucleic acid binding properties, and splicing regulatory function. J. Mol. Biol., 348, 575-588.
21. Kuo, P.H., Doudeva, L.G., Wang, Y.T., Shen, C.K., and Yuan, H.S. (2009) Structural insights into TDP-43 in nucleic-acid binding, and domain interactions. Nucleic Acids Res., 37, 1799-1808.
22. Buratti, E., and Baralle, F.E. (2010) The multiple roles of TDP-43 in pre-mRNA processing, and gene expression regulation. RNA Biol., 7, 420-429.
23. Buratti, E., and Baralle, F.E. (2012) TDP-43: gumming up neurons through protein-protein, and protein-RNA interactions. Trends Biochem. Sci., 37, 237-247.
24. Sreedharan, J., Blair, I.P., Tripathi, V.B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J.C., Williams, K.L., Buratti, E. et al. (2008) TDP-43 mutations in familial, and sporadic amyotrophic lateral sclerosis. Science, 319, 1668-1672.
25. Rutherford, N.J., Zhang, Y.J., Baker, M., Gass, J.M., Finch, N.A., Xu, Y.F., Stewart, H., Kelley, B.J., Kuntz, K., Crook, R.J. et al. (2008) Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet., 4, e1000193.
26. Kabashi, E., Valdmanis, P.N., Dion, P., Spiegelman, D., McConkey, B.J., Vande, V.C., Bouchard, J.P., Lacomblez, L., Pochigaeva, K., Salachas, F. et al. (2008) TARDBP Mutations in individuals with sporadic, and familial amyotrophic lateral sclerosis. Nat. Genet., 40, 572-574.
27. Janssens, J., Kleinberger, G., Wils, H., and VanBroeckhoven, C. (2011) The role of mutant TAR DNA-binding protein 43 in amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Biochem. Soc. Trans., 39, 954-959.
28. Benajiba, L., Le Ber, I, Camuzat, A., Lacoste, M., Thomas-Anterion, C., Couratier, P., Legallic, S., Salachas, F., Hannequin, D., Decousus, M. et al. (2009) TARDBP Mutations in motoneuron disease with frontotemporal lobar degeneration. Ann. Neurol., 65, 470-473.
29. Kovacs, G.G., Murrell, J.R., Horvath, S., Haraszti, L., Majtenyi, K., Molnar, M.J., Budka, H., Ghetti, B., and Spina, S. (2009) TARDBP Variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Mov. Disord., 24, 1843-1847.
30. Borroni, B., Bonvicini, C., Alberici, A., Buratti, E., Agosti, C., Archetti, S., Papetti, A., Stuani, C., Di, L.M., Gennarelli, M., and Padovani, A. (2009) Mutation withinTARDBPleads to frontotemporal dementia without motor neuron disease. Hum. Mutat., 30, E974-E983.
31. Borroni, B., Archetti, S., Del, B.R., Papetti, A., Buratti, E., Bonvicini, C., Agosti, C., Cosseddu, M., Turla, M., Di, L.D. et al. (2010) TARDBP Mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course. Rejuvenation Res., 13, 509-517.
32. Cruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.J. et al. (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature, 442, 920-924.
33. Baker, M., Mackenzie, I.R., Pickering-Brown, S.M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson,J., Sadovnick, A.D., Rollinson, S. et al. (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 442, 916-919.
34. Greenway, M.J., Andersen, P.M., Russ, C., Ennis, S., Cashman, S., Donaghy, C., Patterson, V., Swingler, R., Kieran, D., Prehn, J. et al. (2006) ANGMutations segregate with familial, and 'sporadic' amyotrophic lateral sclerosis. Nat. Genet., 38, 411-413.
35. Kim, H.J., Kim, N.C., Wang, Y.D., Scarborough, E.A., Moore, J., Diaz, Z., MacLea, K.S., Freibaum, B., Li, S., Molliex, A. et al. (2013) Mutations in prion-like domains in hnRNPA2B1, and hnRNPA1 cause multisystem proteinopathy, and ALS. Nature, 495, 467-473.
36. Maruyama, H., Morino, H., Ito, H., Izumi, Y., Kato, H., Watanabe, Y., Kinoshita, Y., Kamada, M., Nodera, H., Suzuki, H. et al. (2010) Mutations of optineurin in amyotrophic lateral sclerosis. Nature, 465, 223-226.
37. Deng, H.X., Chen, W., Hong, S.T., Boycott, K.M., Gorrie, G.H., Siddique, N., Yang, Y., Fecto, F., Shi, Y., Zhai, H. et al. (2011) Mutations inUBQLN2 cause dominant X-linked juvenile, and adult-onsetALSand ALS/dementia. Nature, 477, 211-215.
38. Fecto, F., Yan, J., Vemula, S.P., Liu, E., Yang, Y., Chen, W., Zheng, J.G., Shi, Y., Siddique, N., Arrat, H. et al. (2011)SQSTM1Mutations in familial, and sporadic amyotrophic lateral sclerosis. Arch. Neurol., 68, 1440-1446.
39. Rubino, E., Rainero, I., Chio, A., Rogaeva, E., Galimberti, D., Fenoglio, P., Grinberg, Y., Isaia, G., Calvo, A., Gentile, S. et al. (2012) SQSTM1 Mutations in frontotemporal lobar degeneration, and amyotrophic lateral sclerosis. Neurology, 79, 1556-1562.
40. Watts, G.D., Wymer, J., Kovach, M.J., Mehta, S.G., Mumm, S., Darvish, D., Pestronk, A., Whyte, M.P., and Kimonis, V.E. (2004) Inclusion body myopathy associated with Paget disease of bone, and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet., 36, 377-381.
41. Johnson, J.O., Mandrioli, J., Benatar, M., Abramzon, Y., Van Deerlin, V.M., Trojanowski, J.Q., Gibbs, J.R., Brunetti, M., Gronka, S.,Wuu,J. et al. (2010) Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron, 68, 857-864.
42. King, O.D., Gitler, A.D., and Shorter, J. (2012) The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res., 1462, 61-80.
43. Thomas, M., Alegre-Abarrategui, J., and Wade-Martins, R. (2013) RNA Dysfunction, and aggrephagy at the centre of an amyotrophic lateral sclerosis/frontotemporal dementia disease continuum. Brain, 136, 1345-1360.
44. Gijselinck, I., Van, L.T., van der Zee, J., Sleegers, K., Philtjens, S., Kleinberger, G., Janssens, J., Bettens, K., Van, C.C., Pereson, S. et al. (2012) A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol., 11, 54-65.
45. Renton, A.E., Majounie, E., Waite, A., Simon-Sanchez, J., Rollinson, S., Gibbs, J.R., Schymick, J.C., Laaksovirta, H., van Swieten, J.C., Myllykangas, L. et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron, 72, 257-268.
46. DeJesus-Hernandez, M., Mackenzie, I.R., Boeve, B.F., Boxer, A.L., Baker, M., Rutherford, N.J., Nicholson, A.M., Finch, N.A., Flynn, H., Adamson, J. et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linkedFTD, and ALS. Neuron, 72, 245-256.
47. Van Hoecke, A., Schoonaert, L., Lemmens, R., Timmers, M., Staats, K.A., Laird, A.S., Peeters, E., Philips, T., Goris, A., Dubois, B. et al. (2012) EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models, and in humans. Nat. Med., 18, 1418-1422.
48. Armakola, M., Higgins, M.J., Figley, M.D., Barmada, S.J., Scarborough, E.A., Diaz, Z., Fang, X., Shorter, J., Krogan, N.J., Finkbeiner, S. et al. (2012) Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat. Genet., 44, 1302-1309.
49. Simpson, C.L., Lemmens, R., Miskiewicz, K., Broom, W.J., Hansen, V.K., van Vught, P.W., Landers, J.E., Sapp, P.,Vanden Bosch, L., Knight, J. et al. (2009) Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Hum. Mol. Genet., 18, 472-481.
50. Elden, A.C., Kim, H.J., Hart, M.P., Chen-Plotkin, A.S., Johnson, B.S., Fang, X., Armakola, M., Geser, F., Greene, R., Lu, M.M. et al. (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature, 466, 1069-1075.
51. Bonini, N.M., and Gitler, A.D. (2011) Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS. J. Mol. Neurosci., 45, 676-683.
52. Belzil, V.V., Gendron, T.F., and Petrucelli, L. (2012) RNA-mediated toxicity in neurodegenerative disease. Mol. Cell Neurosci. http://dx.doi. org/10.1016/j.mcn.2012.12.006. [Epub ahead of print].
53. Todd P.K., and Paulson, H.L. (2010) RNA-mediated neurodegeneration in repeat expansion disorders. Ann. Neurol., 67, 291-300.
54. Cooper, T.A., Wan, L., and Dreyfuss, G. (2009) RNA, and disease. Cell, 136, 777-793.
55. Lagier-Tourenne, C., Polymenidou, M., and Cleveland, D.W. (2010) TDP-43, and FUS/TLS: emerging roles in RNA processing, and neurodegeneration. Hum. Mol. Genet., 19, R46-R64.
56. Mackenzie, I.R., Rademakers, R., and Neumann, M. (2010) TDP-43, and FUS in amyotrophic lateral sclerosis, and frontotemporal dementia. Lancet Neurol., 9, 995-1007.
57. Couthouis, J., Hart, M.P., Shorter, J., DeJesus-Hernandez, M., Erion, R., Oristano, R., Liu, A.X., Ramos, D., Jethava, N., Hosangadi, D. et al. (2011) Ayeast functional screen predicts new candidate ALS disease genes. Proc. Natl Acad. Sci. USA, 108, 20881-20890.
58. Neumann, M., Bentmann, E., Dormann, D., Jawaid, A., DeJesus-Hernandez, M., Ansorge, O., Roeber, S., Kretzschmar, H.A., Munoz, D.G., Kusaka, H. et al. (2011) FET Proteins TAF15, and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUSmutations. Brain, 134, 2595-2609.
59. Ticozzi, N., Vance, C., Leclerc, A.L., Keagle, P., Glass, J.D., McKenna-Yasek, D., Sapp, P.C., Silani, V., Bosco, D.A., Shaw, C.E. et al.(2011) Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis. Am. J. Med. Genet. B Neuropsychiatr. Genet., 156B, 285-290.
60. Krecic, A.M., and Swanson, M.S. (1999) hnRNP complexes: composition, structure, and function. Curr. Opin. Cell Biol., 11, 363-371.
61. Buratti, E., Brindisi, A., Giombi, M., Tisminetzky, S., Ayala, Y.M., and Baralle, F.E. (2005) TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J. Biol. Chem., 280, 37572-37584.
62. Tsuiji, H., Iguchi, Y., Furuya, A., Kataoka, A., Hatsuta, H., Atsuta, N., Tanaka, F., Hashizume, Y., Akatsu, H., Murayama, S. et al. (2013) Spliceosome integrity is defective in the motor neuron diseases ALS, and SMA. EMBO Mol. Med., 5, 221-234.
63. Arnold, E.S., Ling, S.C., Huelga, S.C., Lagier-Tourenne, C., Polymenidou, M., Ditsworth, D., Kordasiewicz, H.B., McAlonis-Downes, M., Platoshyn, O., Parone, P.A. et al. (2013) ALS-linked TDP-43 mutations produce aberrant RNA splicing, and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl Acad. Sci. USA, 110, E736-E745.
64. Polymenidou, M., Lagier-Tourenne, C., Hutt, K.R., Huelga, S.C., Moran, J., Liang, T.Y., Ling, S.C., Sun, E., Wancewicz, E., Mazur, C. et al. (2011) Long pre-mRNA depletion, and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci., 14, 459-468.
65. Tollervey, J.R., Curk, T., Rogelj, B., Briese, M., Cereda, M., Kayikci, M., Konig, J., Hortobagyi, T., Nishimura, A.L., Zupunski, V. et al. (2011) Characterizing theRNAtargets, and position-dependent splicing regulation by TDP-43. Nat. Neurosci., 14, 452-458.
66. Bhardwaj, A., Myers, M.P., Buratti, E., and Baralle, F.E. (2013) Characterizing TDP-43 interaction with its RNA targets. Nucleic Acids Res., 41, 5062-5074.
67. Sephton, C.F., Cenik, C., Kucukural, A., Dammer, E.B., Cenik, B., Han, Y., Dewey, C.M., Roth, F.P., Herz, J., Peng, J. et al. (2011) Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J. Biol. Chem., 286, 1204-1215.
68. Schmid, B., Hruscha, A., Hogl, S., Banzhaf-Strathmann, J., Strecker, K., van der Zee, J., Teucke, M., Eimer, S., Hegermann, J., Kittelmann, M. et al. (2013) Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth. Proc. Natl Acad. Sci. USA, 110, 4986-4991.
69. Ayala, Y.M., De, C.L., Avendano-Vazquez, S.E., Dhir, A., Romano, M., D'Ambrogio, A., Tollervey, J., Ule, J., Baralle, M., Buratti, E., and Baralle, F.E. (2011)TDP-43 regulates itsmRNAlevels through a negative feedback loop. EMBO J., 30, 277-288.
70. Avendano-Vazquez, S.E., Dhir, A., Bembich, S., Buratti, E., Proudfoot, N., and Baralle, F.E. (2012) Autoregulation of TDP-43mRNAlevels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Dev., 26, 1679-1684.
71. Budini, M., and Buratti, E. (2011) TDP-43 autoregulation: implications for disease. J. Mol. Neurosci., 45, 473-479.
72. Igaz, L.M., Kwong, L.K., Lee, E.B., Chen-Plotkin, A., Swanson, E., Unger, T., Malunda, J., Xu, Y., Winton, M.J., Trojanowski, J.Q., and Lee, V.M. (2011) Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death, and degeneration in mice. J. Clin. Invest., 121, 726-738.
73. Xu, Y.F., Gendron, T.F., Zhang, Y.J., Lin, W.L., D'Alton, S., Sheng, H., Casey, M.C., Tong, J., Knight, J., Yu, X. et al. (2010) Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci., 30, 10851-10859.
74. Xu, Y.F., Zhang, Y.J., Lin, W.L., Cao, X., Stetler, C., Dickson, D.W., Lewis, J., and Petrucelli, L. (2011) Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol. Neurodegener., 6, 73.
75. Tsai, K.J., Yang, C.H., Fang, Y.H., Cho, K.H., Chien, W.L., Wang, W.T., Wu, T.W., Lin, C.P., Fu, W.M., and Shen, C.K. (2010) Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological, and pathological phenotypes mimicking FTLD-U. J. Exp. Med., 207, 1661- 1673.
76. Janssens, J., Wils, H., Kleinberger, G., Joris, G., Cuijt, I., Ceuterick-de, G.C., Van Broeckhoven, C., and Kumar-Singh, S. (2013) Overexpression of ALS-associated p.M337VhumanTDP-43in mice worsens disease features compared to wild-type human TDP-43 mice. Mol. Neurobiol., 48, 22-35.
77. Wils, H., Kleinberger, G., Janssens, J., Pereson, S., Joris, G., Cuijt, I., Smits, V., Ceuterick-de, G.C., Van Broeckhoven, C., and Kumar-Singh, S. (2010) TDP-43 transgenic mice develop spastic paralysis, and neuronal inclusions characteristic of ALS, and frontotemporal lobar degeneration. Proc. Natl Acad. Sci. USA, 107, 3858-3863.
78. Mishra, M., Paunesku, T., Woloschak, G.E., Siddique, T., Zhu, L.J., Lin, S., Greco, K., and Bigio, E.H. (2007) Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. Acta Neuropathol., 114, 81-94.
79. Gitcho, M.A., Bigio, E.H., Mishra, M., Johnson, N., Weintraub, S., Mesulam, M., Rademakers, R., Chakraverty, S., Cruchaga, C., Morris, J.C. et al. (2009) TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathol., 118, 633-645.
80. Moisse, K., Mepham, J., Volkening, K., Welch, I., Hill, T., and Strong, M.J. (2009) Cytosolic TDP-43 expression following axotomy is associated with caspase 3 activation in NFL2/2 mice: support for a role for TDP-43 in the physiological response to neuronal injury. Brain Res., 1296, 176-186.
81. Moisse, K., Volkening, K., Leystra-Lantz, C., Welch, I., Hill, T., and Strong, M.J. (2009) Divergent patterns of cytosolic TDP-43, and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. Brain Res., 1249, 202-211.
82. Ling, S.C., Albuquerque, C.P., Han, J.S., Lagier-Tourenne, C., Tokunaga, S., Zhou, H., and Cleveland, D.W. (2010) ALS-associated mutations in TDP-43 increase its stability, and promote TDP-43 complexes with FUS/ TLS. Proc. Natl Acad. Sci. USA, 107, 13318-13323.
83. Gijselinck, I., Engelborghs, S., Maes, G., Cuijt, I., Peeters, K., Mattheijssens, M., Joris, G., Cras, P., Martin, J.J., De Deyn, P.P. et al. (2010) Identification of 2 Loci at chromosomes 9, and 14 in a multiplex family with frontotemporal lobar degeneration, and amyotrophic lateral sclerosis. Arch. Neurol., 67, 606-616.
84. Vance, C., Al-Chalabi, A., Ruddy, D., Smith, B.N., Hu, X., Sreedharan, J., Siddique, T., Schelhaas, H.J., Kusters, B., Troost, D. et al. (2006) Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain, 129, 868-876.
85. Morita, M., Al-Chalabi, A., Andersen, P.M., Hosler, B., Sapp, P., Englund, E., Mitchell, J.E., Habgood, J.J., de, B.J., Xi, J. et al. (2006) A locus on chromosome 9p confers susceptibility to ALS, and frontotemporal dementia. Neurology, 66, 839-844.
86. Ishiura, H., Takahashi, Y., Mitsui, J., Yoshida, S., Kihira, T., Kokubo, Y., Kuzuhara, S., Ranum, L.P., Tamaoki, T., Ichikawa, Y. et al. (2012) C9ORF72 repeat expansion in amyotrophic lateral sclerosis in the Kii peninsula of Japan. Arch. Neurol., 69, 1154-1158.
87. Cruts, M., Gijselinck, I., Van, L.T., van der Zee, J., and Van Broeckhoven, C. (2013) Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci. doi:10.1016/j.tins.2013.04.010.
88. Levine, T.P., Daniels, R.D., Gatta, A.T., Wong, L.H., and Hayes, M.J. (2013) The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics, 29, 499-503.
89. Hadano, S., Otomo, A., Kunita, R., Suzuki-Utsunomiya, K., Akatsuka, A., Koike, M., Aoki, M., Uchiyama, Y., Itoyama, Y., and Ikeda, J.E. (2010) Loss of ALS2/alsin exacerbates motor dysfunction in a SOD1-expressing mouse ALS model by disturbing endolysosomal trafficking. PLoS ONE, 5, e9805.
90. Del, V.K., and Miller, C.A. (2004) Down-regulation of DENN/MADD, a TNF receptor binding protein, correlates with neuronal cell death in Alzheimer's disease brain, and hippocampal neurons. Proc. Natl Acad. Sci. USA, 101, 4210-4215.
91. Xu, Z., Poidevin, M., Li, X., Li, Y., Shu, L., Nelson, D.L., Li, H., Hales, C.M., Gearing, M., Wingo, T.S., and Jin, P. (2013) Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis, and frontotemporal dementia causes neurodegeneration. Proc. Natl Acad. Sci. USA, 110, 7778-7783.
92. Xi, Z., Zinman, L., Moreno, D., Schymick, J., Liang, Y., Sato, C., Zheng, Y., Ghani, M., Dib, S., Keith, J. et al. (2013) Hypermethylation of the CpG Island near the GC repeat in ALS with a C9orf72 expansion. Am. J. Hum. Genet., 92, 981-989.
93. van der Zee, J., Gijselinck, I., Dillen, L., Van, L.T., Theuns, J., Engelborghs, S., Philtjens, S., Vandenbulcke, M., Sleegers, K., Sieben, A. et al. (2013)A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum. Mutat., 34, 363-373.
94. Simon-Sanchez, J., Dopper, E.G., Cohn-Hokke, P.E., Hukema, R.K., Nicolaou, N., Seelaar, H., de Graaf, J.R., de Koning, I, van Schoor, N.M.,Deeg, D.J. et al. (2012) The clinical, and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain, 135, 723-735.
95. Mori, K., Lammich, S., Mackenzie, I.R., Forne, I., Zilow, S., Kretzschmar, H., Edbauer, D., Janssens, J., Kleinberger, G., Cruts,M.et al. (2013)hnRNP A3 binds to GGGGCC repeats, and is a constituent of p62-positive/ TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathol., 125, 413-423.
96. Sofola, O.A., Jin, P., Qin, Y., Duan, R., Liu, H., de, H.M., Nelson, D.L., and Botas, J. (2007) RNA-binding proteins hnRNP A2/B1, and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron, 55, 565-571.
97. Al-Sarraj, S., King, A., Troakes, C., Smith, B., Maekawa, S., Bodi, I., Rogelj, B., Al-Chalabi, A., Hortobagyi, T., and Shaw, C.E. (2011) P62 positive, TDP-43 negative, neuronal cytoplasmic, and intranuclear inclusions in the cerebellum, and hippocampus define the pathology of C9orf72-linked FTLD, and MND/ALS. Acta Neuropathol., 122, 691-702.
98. King, A., Maekawa, S., Bodi, I., Troakes, C., and Al-Sarraj, S. (2011) Ubiquitinated, p62 immunopositive cerebellar cortical neuronal inclusions are evident across the spectrum of TDP-43 proteinopathies but are only rarely additionally immunopositive for phosphorylation-dependent TDP-43. Neuropathology, 31, 239-249.
99. Troakes, C., Maekawa, S., Wijesekera, L., Rogelj, B., Siklos, L., Bell, C., Smith, B., Newhouse, S., Vance, C., Johnson, L. et al. (2012) An MND/ ALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus, and cerebellum but without associated cognitive decline. Neuropathology, 32, 505-514.
100. Mori, K., Weng, S.M., Arzberger, T., May, S., Rentzsch, K., Kremmer, E., Schmid, B., Kretzschmar, H.A., Cruts, M., Van Broeckhoven, C. et al. (2013) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science, 339, 1335-1338.
101. Ash, P.E., Bieniek, K.F., Gendron, T.F., Caulfield, T., Lin, W.L., DeJesus-Hernandez, M., van Blitterswijk, M.M., Jansen-West, K., Paul, J.W. III, Rademakers, R. et al. (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron, 77, 639-646.
102. Zu, T., Gibbens, B., Doty, N.S., Gomes-Pereira, M., Huguet, A., Stone, M.D., Margolis, J., Peterson, M., Markowski, T.W., Ingram, M.A. et al. (2011) Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl Acad. Sci. USA, 108, 260-265.
103. Fratta, P., Mizielinska, S., Nicoll, A.J., Zloh, M., Fisher, E.M., Parkinson, G., and Isaacs, A.M. (2012) C9orf72 hexanucleotide repeat associated with amyotrophic lateral sclerosis, and frontotemporal dementia forms RNA G-quadruplexes. Sci. Rep., 2, 1016.
104. Reddy, K., Zamiri, B., Stanley, S.Y., Macgregor, R.B. Jr, and Pearson, C.E. (2013) The disease-associatedr(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni-, and multimolecular RNA G-quadruplex structures. J. Biol. Chem., 288, 9860-9866.
105. Barmada, S.J., Skibinski, G., Korb, E., Rao, E.J., Wu, J.Y., and Finkbeiner, S. (2010) Cytoplasmic mislocalization of TDP-43 is toxic to neurons, and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci., 30, 639-649.
106. Uchida, A., Sasaguri, H., Kimura, N., Tajiri, M., Ohkubo, T., Ono, F., Sakaue, F., Kanai, K., Hirai, T., Sano, T. et al. (2012) Non-human primate model of amyotrophic lateral sclerosis with cytoplasmic mislocalization of TDP-43. Brain, 135, 833-846.
107. Ayala, Y.M., Zago, P., D'Ambrogio, A., Xu, Y.F., Petrucelli, L., Buratti, E., and Baralle, F.E. (2008) Structural determinants of the cellular localization, and shuttling of TDP-43. J. Cell Sci., 121, 3778-3785.
108. Winton, M.J., Igaz, L.M., Wong, M.M., Kwong, L.K., Trojanowski, J.Q., and Lee, V.M. (2008) Disturbance of nuclear, and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem., 283, 13302-13309.
109. Ritson, G.P., Custer, S.K., Freibaum, B.D., Guinto, J.B., Geffel, D., Moore, J., Tang, W., Winton, M.J., Neumann, M., Trojanowski, J.Q. et al. (2010) TDP-43 mediates degeneration in a novel drosophila model of disease caused by mutations in VCP/p97. J. Neurosci., 30, 7729-7739.
110. Guo, W., Chen, Y., Zhou, X., Kar, A., Ray, P., Chen, X., Rao, E.J., Yang, M., Ye, H., Zhu, L. et al. (2011) An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation, and neurotoxicity. Nat. Struct. Mol. Biol., 18, 822-830.
111. Fallini, C., Bassell, G.J., and Rossoll, W. (2012) The ALS disease protein TDP-43 is actively transported in motor neuron axons, and regulates axon outgrowth. Hum. Mol. Genet., 21, 3703-3718.
112. Dormann, D., and Haass, C. (2011) TDP-43, and FUS: a nuclear affair. Trends Neurosci., 34, 339-348.
113. Dormann, D., Rodde, R., Edbauer, D., Bentmann, E., Fischer, I., Hruscha, A., Than, M.E., Mackenzie, I.R., Capell, A., Schmid, B. et al. (2010) ALS-associated fused in sarcoma (FUS) mutations disrupt transportin-mediated nuclear import. EMBO J., 29, 2841-2857.
114. Johnson, B.S., Snead, D., Lee, J.J., McCaffery, J.M., Shorter, J., and Gitler, A.D. (2009) TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation, and increase toxicity. J. Biol. Chem., 284, 20329-20339.
115. Nonaka, T., Kametani, F., Arai, T., Akiyama, H., and Hasegawa, M. (2009) Truncation, and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum. Mol. Genet., 18, 3353-3364.
116. Johnson, B.S., McCaffery, J.M., Lindquist, S., and Gitler, A.D. (2008) A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation, and cellular toxicity. Proc. Natl Acad. Sci. USA, 105, 6439-6444.
117. Saini, A., and Chauhan, V.S. (2011) Delineation of the core aggregation sequences of TDP-43 C-terminal fragment. Chembiochem, 12, 2495-2501.
118. Zhang, Y.J., Caulfield, T., Xu, Y.F., Gendron, T.F., Hubbard, J., Stetler, C., Sasaguri, H., Whitelaw, E.C., Cai, S., Lee, W.C., and Petrucelli, L. (2013) The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity, and inclusion formation. Hum. Mol. Genet., 22, 3112-3122.
119. Wang, Y.T., Kuo, P.H., Chiang, C.H., Liang, J.R., Chen, Y.R., Wang, S., Shen, J.C., and Yuan, H.S. (2013) The truncated C-terminal RNA recognition motif of TDP-43 protein plays a key role in forming proteinaceous aggregates. J. Biol. Chem., 288, 9049-9057.
120. Shodai, A., Morimura, T., Ido, A., Uchida, T., Ayaki, T., Takahashi, R., Kitazawa, S., Suzuki, S., Shirouzu, M., Kigawa, T. et al. (2013) Aberrant assembly of RNA recognition motif 1 links to pathogenic conversion of TAR DNA-binding protein of 43 kDa (TDP-43). J. Biol. Chem., 288, 14886-14905.
121. Voigt, A., Herholz, D., Fiesel, F.C., Kaur, K., Muller, D., Karsten, P., Weber, S.S., Kahle, P.J., Marquardt, T., and Schulz, J.B. (2010) TDP-43-mediated neuron loss in vivo requires RNA-binding activity.PLoS ONE, 5, e12247.
122. Cushman, M., Johnson, B.S., King, O.D., Gitler, A.D., and Shorter, J. (2010) Prion-like disorders: blurring the divide between transmissibility, and infectivity. J. Cell Sci., 123, 1191-1201.
123. Fuentealba, R.A., Udan, M., Bell, S., Wegorzewska, I., Shao, J., Diamond, M.I., Weihl, C.C., and Baloh, R.H. (2010) Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. J. Biol. Chem., 285, 26304-26314.
124. Polymenidou, M., and Cleveland, D.W. (2011) The seeds of neurodegeneration: prion-like spreading in ALS. Cell, 147, 498-508.
125. Colby, D.W., and Prusiner, S.B. (2011) Prions. Cold Spring Harb. Perspect. Biol., 3, a006833.
126. Alberti, S., Halfmann, R., King, O., Kapila, A., and Lindquist, S. (2009) A systematic survey identifies prions, and illuminates sequence features of prionogenic proteins. Cell, 137, 146-158.
127. Toombs, J.A., McCarty, B.R., and Ross, E.D. (2010) Compositional determinants of prion formation in yeast. Mol. Cell Biol., 30, 319-332.
128. Ravits, J., Paul, P., and Jorg, C. (2007) Focality of upper, and lower motor neuron degeneration at the clinical onset of ALS. Neurology, 68, 1571- 1575.
129. Ravits, J.M., and La Spada, A.R. (2009) ALS Motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology, 73, 805-811.
130. Kwong, L.K., Uryu, K., Trojanowski, J.Q., and Lee, V.M. (2008) TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. Neurosignals, 16, 41-51.
131. Chen, A.K., Lin, R.Y., Hsieh, E.Z., Tu, P.H., Chen, R.P., Liao, T.Y., Chen, W., Wang, C.H., and Huang, J.J. (2010) Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J. Am. Chem. Soc., 132, 1186-1187.
132. Bigio, E.H., Wu, J.Y., Deng, H.X., Bit-Ivan, E.N., Mao, Q., Ganti, R., Peterson, M., Siddique, N., Geula, C., Siddique, T., and Mesulam,M.(2013) Inclusions in frontotemporal lobar degeneration with TDP-43proteinopathy (FTLD-TDP), and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathol., 125, 463-465.
133. Jiang, L.L., Che, M.X., Zhao, J., Zhou, C.J., Xie, M.Y., Li, H.Y., He, J.H., and Hu, H.Y. (2013) Structural transformation of the amyloidogenic core region of TAR DNA binding protein of 43 kDa (TDP-43) initiates Its aggregation, and cytoplasmic inclusion. J. Biol. Chem., 288, 19614-19624.
134. Wang, I.F., Chang, H.Y., Hou, S.C., Liou, G.G., Way, T.D., and James Shen, C.K. (2012) The self-interaction of native TDP-43 C terminus inhibits its degradation, and contributes to early proteinopathies. Nat. Commun., 3, 766.
135. Wolozin, B. (2012) Regulated protein aggregation: stress granules, and neurodegeneration. Mol. Neurodegener., 7, 56.
136. Bentmann, E., Haass, C., and Dormann, D. (2013) Stress granules in neurodegeneration - lessons learnt from TAR DNA binding protein of 43 kDa, and fused in sarcoma. FEBS J. doi: 10.1111/febs.12287.
137. Colombrita, C., Zennaro, E., Fallini, C., Weber, M., Sommacal, A., Buratti, E., Silani, V., and Ratti, A. (2009) TDP-43 is recruited to stress granules in conditions of oxidative insult. J. Neurochem., 111, 1051-1061.
138. Liu-Yesucevitz, L., Bilgutay, A., Zhang, Y.J., Vanderweyde, T., Citro, A., Mehta, T., Zaarur, N., McKee, A., Bowser, R., Sherman, M. et al. (2010) Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells, and pathological brain tissue. PLoS ONE, 5, e13250.
139. Dewey, C.M., Cenik, B., Sephton, C.F., Dries, D.R., Mayer, P. III, Good, S.K., Johnson, B.A., Herz, J., and Yu, G. (2011) TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic, and oxidative stressor. Mol. Cell Biol., 31, 1098-1108.
140. McDonald, K.K., Aulas, A., Destroismaisons, L., Pickles, S., Beleac, E., Camu, W., Rouleau, G.A., and Vande, V.C. (2011) TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP, and TIA-1. Hum. Mol. Genet., 20, 1400-1410.
141. Bentmann, E., Neumann, M., Tahirovic, S., Rodde, R., Dormann, D., and Haass, C. (2012) Requirements for stress granule recruitment of fused in sarcoma (FUS), and TAR DNA-binding protein of 43 kDa (TDP-43). J. Biol. Chem., 287, 23079-23094.
142. Parker, S.J., Meyerowitz, J., James, J.L., Liddell, J.R., Crouch, P.J., Kanninen, K.M., and White, A.R. (2012) Endogenous TDP-43 localized to stress granules can subsequently form protein aggregates. Neurochem. Int., 60, 415-424.
143. Pesiridis, G.S., Tripathy, K., Tanik, S., Trojanowski, J.Q., and Lee, V.M. (2011) A "two-hit" hypothesis for inclusion formation by carboxyl-terminal fragments of TDP-43 protein linked to RNA depletion, and impaired microtubule-dependent transport. J. Biol. Chem., 286, 18845-18855.
144. Miguel, L., Frebourg, T., Campion, D., and Lecourtois, M. (2011) Both cytoplasmic, and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies. Neurobiol. Dis., 41, 398- 406.
145. Nishihira, Y., Tan, C.F., Toyoshima, Y., Yonemochi, Y., Kondo, H., Nakajima, T., and Takahashi, H. (2009) Sporadic amyotrophic lateral sclerosis: widespread multisystem degeneration with TDP-43 pathology in a patient after long-term survival on a respirator. Neuropathology, 29, 689- 696.
146. Sephton, C.F., Good, S.K., Atkin, S., Dewey, C.M., Mayer, P. III, Herz, J., and Yu, G. (2010) TDP-43 is a developmentally regulated protein essential for early embryonic development. J. Biol. Chem., 285, 6826-6834.
147. Wu, L.S., Cheng, W.C., Hou, S.C., Yan, Y.T., Jiang, S.T., and Shen, C.K. (2010) TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis. Genesis, 48, 56-62.
148. Kraemer, B.C., Schuck, T., Wheeler, J.M., Robinson, L.C., Trojanowski, J.Q., Lee, V.M., and Schellenberg, G.D. (2010) Loss of murine TDP-43 disrupts motor function, and plays an essential role in embryogenesis. Acta Neuropathol., 119, 409-419.
149. Huang, C., Xia, P.Y., and Zhou, H. (2010) Sustained expression of TDP-43 andFUSin motor neurons in rodent's lifetime. Int. J. Biol. Sci., 6, 396-406.
150. Huang, C., Tong, J., Bi, F., Zhou, H., and Xia, X.G. (2012) Mutant TDP-43 in motor neurons promotes the onset, and progression ofALSin rats. J. Clin. Invest., 122, 107-118.
151. Watanabe, S., Kaneko, K., and Yamanaka, K. (2013) Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins. J. Biol. Chem., 288, 3641-3654.
152. Almeida, S., Zhang, Z., Coppola, G., Mao, W., Futai, K., Karydas, A., Geschwind, M.D., Tartaglia, M.C., Gao, F., Gianni, D. et al. (2012) Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep., 2, 789-798.
153. Bilican, B., Serio, A., Barmada, S.J., Nishimura, A.L., Sullivan, G.J., Carrasco, M., Phatnani, H.P., Puddifoot, C.A., Story, D., Fletcher, J. et al. (2012) Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies, and reveal cell-specific vulnerability. Proc. Natl Acad. Sci. USA, 109, 5803-5808.
154. Rubinsztein, D.C. (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature, 443, 780-786.
155. Blokhuis, A.M., Groen, E.J., Koppers, M., van den Berg, L.H., and Pasterkamp, R.J. (2013) Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol., 125, 777-794.
156. Chen, S., Zhang, X., Song, L., and Le, W. (2012) Autophagy dysregulation in amyotrophic lateral sclerosis. Brain Pathol., 22, 110-116.
157. Wang, X., Fan, H., Ying, Z., Li, B., Wang, H., and Wang, G. (2010) Degradation of TDP-43, and its pathogenic form by autophagy, and the ubiquitin-proteasome system. Neurosci. Lett., 469, 112-116.
158. van, E.J., Ke, Y.D., Gladbach, A., Bi, M., Gotz, J., Kril, J.J., and Ittner, L.M. (2011) Cytoplasmic accumulation, and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. PLoS ONE, 6, e22850.
159. Brady, O.A., Meng, P., Zheng, Y., Mao, Y., and Hu, F. (2011) Regulation of TDP-43 aggregation by phosphorylation, and p62/SQSTM1. J. Neurochem., 116, 248-259.
160. Tanji, K., Zhang, H.X., Mori, F., Kakita, A., Takahashi, H., and Wakabayashi, K. (2012) P62/sequestosome 1 binds to TDP-43 in brains with frontotemporal lobar degeneration with TDP-43 inclusions. J. Neurosci. Res., 90, 2034-2042.
161. Tashiro, Y., Urushitani, M., Inoue, H., Koike, M., Uchiyama, Y., Komatsu, M., Tanaka, K., Yamazaki, M., Abe, M., Misawa, H. et al. (2012) Motor neuron-specific disruption of proteasomes, but not autophagy, replicates amyotrophic lateral sclerosis. J. Biol. Chem., 287, 42984-42994.
162. Tong, J., Huang, C., Bi, F., Wu, Q., Huang, B., and Zhou, H. (2012) XBP1 Depletion precedes ubiquitin aggregation, and Golgi fragmentation in TDP-43 transgenic rats. J. Neurochem., 123, 406-416.
163. Taylor, R.C., and Dillin, A. (2013) XBP-1 Is a cell-nonautonomous regulator of stress resistance, and longevity. Cell, 153, 1435-1447.
164. Cruts, M., Theuns, J., and Van Broeckhoven, C. (2012) Locus-specific mutation databases for neurodegenerative brain diseases. Hum. Mutat., 33, 1340-1344.
165. Kwiatkowski, T.J. Jr., Bosco, D.A., Leclerc, A.L., Tamrazian, E., Vanderburg, C.R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E.J., Munsat, T. et al. (2009) Mutations in the FUS/TLSgene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science, 323, 1205-1208.
166. Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K.J., Nishimura, A.L., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P. et al. (2009) Mutations in FUS, anRNAprocessing protein, cause familial amyotrophic lateral sclerosis type 6. Science, 323, 1208-1211.
167. Aparicio-Erriu, I.M., and Prehn, J.H. (2012) Molecular mechanisms in amyotrophic lateral sclerosis: the role of angiogenin, a secreted RNase. Front Neurosci., 6, 167.
168. Hart, M.P., and Gitler, A.D. (2012) ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation, and increase TDP-43 pathological modifications. J. Neurosci., 32, 9133-9142.
169. Kleinberger, G., Capell, A., Haass, C., and Van Broeckhoven, C. (2013) Mechanisms of granulin deficiency: lessons from cellular, and animal models. Mol. Neurobiol., 47, 337-360.